| scholarly article | Q13442814 |
| P50 | author | Mark W. Ball | Q41496168 |
| P2093 | author name string | Eric A Singer | |
| Ramaprasad Srinivasan | |||
| P2860 | cites work | On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models | Q27727998 |
| Nivolumab plus ipilimumab in advanced melanoma | Q27852310 | ||
| Comprehensive molecular characterization of clear cell renal cell carcinoma | Q27852374 | ||
| The somatic genomic landscape of chromophobe renal cell carcinoma | Q28246658 | ||
| Sunitinib versus interferon alfa in metastatic renal-cell carcinoma | Q28282757 | ||
| Sorafenib in advanced clear-cell renal-cell carcinoma | Q28282767 | ||
| Cancer statistics, 2016 | Q29547383 | ||
| Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial | Q29615711 | ||
| Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma | Q29618608 | ||
| Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206 | Q33813718 | ||
| Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival | Q34021957 | ||
| The genetic basis of kidney cancer: a metabolic disease | Q34087148 | ||
| Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET. | Q34217927 | ||
| The changing natural history of renal cell carcinoma | Q34391104 | ||
| Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma | Q34495684 | ||
| PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma | Q34577802 | ||
| Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. | Q34633525 | ||
| Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy | Q34723863 | ||
| PD-L1 expression in nonclear-cell renal cell carcinoma | Q34882798 | ||
| Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma | Q35009888 | ||
| Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma | Q35413876 | ||
| The genetic basis of cancer of the kidney | Q35591611 | ||
| Mini-review: overcoming tumor-intrinsic resistance to immune effector function. | Q35887878 | ||
| Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained | Q36186882 | ||
| Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. | Q36281483 | ||
| Variability of inter-observer agreement on feasibility of partial nephrectomy before and after neoadjuvant axitinib for locally advanced renal cell carcinoma (RCC): independent analysis from a phase II trial | Q36338821 | ||
| Genetic basis of kidney cancer: role of genomics for the development of disease-based therapeutics | Q36354841 | ||
| Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma | Q36642291 | ||
| The relationship between T-lymphocyte infiltration, stage, tumour grade and survival in patients undergoing curative surgery for renal cell cancer. | Q36671566 | ||
| Improving our understanding of papillary renal cell carcinoma with integrative genomic analysis | Q36829230 | ||
| Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial | Q36932216 | ||
| Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial | Q36932702 | ||
| PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells | Q36986702 | ||
| Precision Oncology: Identifying Predictive Biomarkers for the Treatment of Metastatic Renal Cell Carcinoma | Q37179808 | ||
| Sequential therapy in renal cell carcinoma | Q37463902 | ||
| Targeting renal cell carcinoma with a HIF-2 antagonist. | Q37684974 | ||
| Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors | Q37765246 | ||
| The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours | Q38758269 | ||
| Recent advances in immunotherapy for kidney cancer | Q38845997 | ||
| Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. | Q38917870 | ||
| Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy | Q38975732 | ||
| Up-regulation of functional chemokine receptor CCR3 in human renal cell carcinoma. | Q40438120 | ||
| Tumour necrosis factor-alpha, interleukin-1 beta and interleukin-6 in patients with renal cell carcinoma | Q40706895 | ||
| Safety and Efficacy of Pazopanib Therapy Prior to Planned Nephrectomy in Metastatic Clear Cell Renal Cancer. | Q40722561 | ||
| Immunotherapy earns its spot in the ranks of cancer therapy | Q41183693 | ||
| Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma | Q41316099 | ||
| Spontaneous regression of metastatic renal cancer. Case report and literature review | Q41562595 | ||
| Immunological effects of multikinase inhibitors for kidney cancer: a clue for integration with cellular therapies? | Q42158701 | ||
| Sorafenib induces autophagy and suppresses activation of human macrophage | Q45203186 | ||
| Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas | Q45345804 | ||
| Pathobiology and prognosis of chromophobe renal cell carcinoma | Q46682020 | ||
| Chromophobe renal cell carcinoma: a clinicopathologic study of 203 tumors in 200 patients with primary resection at a single institution. | Q53286650 | ||
| First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)†. | Q53567890 | ||
| Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial | Q59571527 | ||
| The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus | Q83514448 | ||
| P921 | main subject | renal cell carcinoma | Q1164529 |
| P577 | publication date | 2017-03-01 | |
| P1433 | published in | Current Opinion in Oncology | Q1909046 |
| P1476 | title | Renal cell carcinoma: molecular characterization and evolving treatment paradigms |
| Q64996867 | Analysis of Expression Patterns of MicroRNAs That Are Closely Associated With Renal Carcinogenesis. |
| Q64095225 | Current Status of Immunotherapy for Localized and Locally Advanced Renal Cell Carcinoma |
| Q49630323 | Prognostic Significance of Pre- to Postoperative Dynamics of the Prognostic Nutritional Index for Patients with Renal Cell Carcinoma Who Underwent Radical Nephrectomy |
| Q64238160 | Resistance to lysosomotropic drugs used to treat kidney and breast cancers involves autophagy and inflammation and converges in inducing CXCL5 |
| Q64074055 | Strengthening the foundation of kidney cancer treatment and research: revising the AJCC staging system |
Search more.